Cholinesterase inhibitor and N-methyl-d-aspartic acid receptor antagonist use in older adults with end-stage dementia: A survey of hospice medical directors

Journal of Palliative Medicine

Volumn 12, Issue 9, 2009, Pages 779-783

  Shega, Joseph W ^a   Ellner, Lynn ^b   Lau, Denys T ^c   Maxwell, Terri L ^d  

^a UNIVERSITY OF CHICAGO   (United States)

^b Midwest Palliative and Hospice CareCenter   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d excelleRx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; RIVASTIGMINE; ANTIPARKINSON AGENT; INDAN DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PIPERIDINE DERIVATIVE;

ADMINISTRATIVE PERSONNEL; AGING; ARTICLE; CAREGIVER BURDEN; DEMENTIA; DISEASE SEVERITY; DRUG USE; DRUG WITHDRAWAL; FAMILY ATTITUDE; HOSPICE CARE; HUMAN; PALLIATIVE THERAPY; PRESCRIPTION; PROFESSIONAL PRACTICE; THERAPY EFFECT; AGE; AGED; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; FEMALE; HEALTH CARE SURVEY; HEALTH STATUS INDICATOR; MALE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CHOLINESTERASE INHIBITORS; DEMENTIA; FEMALE; HEALTH CARE SURVEYS; HEALTH STATUS INDICATORS; HOSPICE CARE; HUMANS; INDANS; MALE; MEMANTINE; PALLIATIVE CARE; PHYSICIAN EXECUTIVES; PIPERIDINES; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 70350093816     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2009.0059     Document Type: Article

References (13)

1. Holmes HM, Hayley DC, Alexander GC, Sachs GA: Reconsidering medication appropriateness for patients late in life. Arch Intern Med 2006;166:605-609.
2. Weschules JD, Maxwell T, Shega JW: Acetylcholinesterase inhibitor and NMDA receptor antagonist use among hospice enrollees with a primary diagnosis of dementia. J Palliat Med 2008;11:738-745.
3. Winblad B, Kilander L, Eriksson S, Minthon L, Ba°tsman S, Wetterholm AL, Jansson-Blixt C, Haglund A; Severe Alzheimer's Disease Study Group: Donepezil in patients with severe Alzheimer's disease: Double-blind, parallel-group, placebo-controlled study. Lancet 2006;367:1057-1065
4. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001;57: 613-620.
5. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ; Memantine Study Group: Memantine in moderate-tosevere Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
6. Tariot PN, Farlow, MR, Grossberg GT: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: A randomized controlled trial. JAMA 2004;291:317-324.
7. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, Booker L, Oremus M: Effectiveness of cholinesterase inhibitors and memantine for treating dementia: Evidence review for a clinical practice guideline. Ann Intern Med 2008;148:379-397.
8. Herrmann N, Gill S, Bell C, Anderson GM, Bronskill SE, Shulman KI, Fischer HD, Sykora K, Shi HS, Rochon PA: A population-based study of cholinesterase inhibitor use for dementia. J Am Geriatr Soc 2007;55:1517-1523.
9. Pedone C, Lapane KL, Mor V, Bernabei R: Donepezil use in US nursing homes. Aging Clin Exp Res 2004;16:60-67.
10. Greenberg SM. Tennis MK. Brown LB, Gomez-Isla T, Hayden DL, Schoenfeld DA, Walsh KL, Corwin C, Daffner KR, Friedman P, Meadows ME, Sperling RA, Growdon JH: Donepezil therapy in clinical practice: A randomized crossover study. Arch Neurol 2000;57:94-99.
11. Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, Pandita-Gunawardena ND, Hogg F, Clare C, Damms J: The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurology 2004;63:214-219.
12. Doody RS. Geldmaacher DS, Gordon B, Perdomo CA, Pratt RD; Donepezil Study Group: Open- label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427-433.
13. Asch D, Jedrziewski K, Christakis N: Response rates to mail surveys published in medical journals. J Clin Epidemiol 1997;54:1129-1136.